<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Y. S. R. Krishnaiah</style></author><author><style face="normal" font="default" size="100%">B. Rama</style></author><author><style face="normal" font="default" size="100%">V. Raghumurthy</style></author><author><style face="normal" font="default" size="100%">K. V. Ramana Murthy</style></author><author><style face="normal" font="default" size="100%">V. Satyanarayana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of PEG6000 on the in vitro and in vivo transdermal permeation of ondansetron hydrochloride from EVA1802 membranes</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceutical Development and Technology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">carvone</style></keyword><keyword><style  face="normal" font="default" size="100%">limonene</style></keyword><keyword><style  face="normal" font="default" size="100%">nerodilol</style></keyword><keyword><style  face="normal" font="default" size="100%">Ondansetron Hydrochloride</style></keyword><keyword><style  face="normal" font="default" size="100%">penetration enhancers</style></keyword><keyword><style  face="normal" font="default" size="100%">Studies on Optimizing In Vitro Transdermal Permeation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><section><style face="normal" font="default" size="100%">50</style></section><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">50</style></pages><abstract><style face="normal" font="default" size="100%">The present investigation was carried out to formulate a terpene-based hydroxypropyl cellulose (HPC) gel drug reservoir system for its optimal transdermal permeation of ondansetron hydrochloride. The HPC gel formulations containing ondansetron hydrochloride (3% w/w) and selected concentrations of either nerodilol (0% w/w, 1% w/w, 2% w/w, 3% w/w, and 4% w/w), carvone (0% w/w, 2% w/w, 4% w/w, 8% w/w, and 10% w/w), or limonene (0% w/w, 2% w/w, 3% w/w, and 4% w/w) were prepared and subjected to in vitro permeation of the drug across rat epidermis. All the 3 terpene enhancers increased the transdermal permeation of ondansetron hydrochloride. The optimal transdermal permeation was observed with 3% w/w of nerodilol (175.3 ± 3.1 μg/cm2.h), 8% w/w of carvone (87.4 ± 1.6 μg/cm2.h), or 3% w/w of limonene (181.9 ± 0.9 μg/cm2.h). The enhancement ratio (ER) in drug permeability with 3% w/w nerodilol, 8% w/w carvone, and 3% w/w limonene were 21.6, 10.8, and 22.5, respectively, when compared with that obtained without a terpene enhancer (control). However, there was 1.04-, 2.09-, and 2.17-fold increase in the optimal drug flux obtained with carvone, nerodilol, and limonene, respectively, when compared with the desired drug flux (84 μg/cm2.h). It was concluded that the HPC gel drug reservoir systems containing either 3% w/w nerodilol or 3% w/w limonene act as optimal formulations for use in the design of membrane-controlled transdermal therapeutic system (TTS) of ondansetron hydrochloride.
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>